201 related articles for article (PubMed ID: 23172714)
1. Factors associated with spontaneous reporting of adverse drug reactions in Japan.
Yamada T; Watanabe Y; Kusama M; Sugiyama Y; Ono S
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):468-76. PubMed ID: 23172714
[TBL] [Abstract][Full Text] [Related]
2. Bias in spontaneous reporting of adverse drug reactions in Japan.
Matsuda S; Aoki K; Kawamata T; Kimotsuki T; Kobayashi T; Kuriki H; Nakayama T; Okugawa S; Sugimura Y; Tomita M; Takahashi Y
PLoS One; 2015; 10(5):e0126413. PubMed ID: 25933226
[TBL] [Abstract][Full Text] [Related]
3. [Organization and results of drug vigilance in France].
Bégaud B; Chaslerie A; Haramburu F
Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
[TBL] [Abstract][Full Text] [Related]
4. [Use of the capture-recapture method to assess the frequency of "serious" adverse drug reactions: experience of Toulouse University Hospital].
Montastruc JL; Lugardon S; Desboeuf K; Fernet P; Lapeyre-Mestre M
Bull Acad Natl Med; 2008 Feb; 192(2):421-30; discussion 430-1. PubMed ID: 18819693
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006.
Sommet A; Durrieu G; Lapeyre-Mestre M; Montastruc JL;
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):285-8. PubMed ID: 22162094
[TBL] [Abstract][Full Text] [Related]
6. Post-approval appending of CSARs to drug package inserts: an analysis of the types of adverse reactions and time to addition.
Tamura N; Ishiguro C; Matsuda T
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):166-75. PubMed ID: 24737526
[TBL] [Abstract][Full Text] [Related]
7. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
8. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay?
Yamada T; Kusama M; Hirai Y; Arnold F; Sugiyama Y; Ono S
Ann Pharmacother; 2010 Dec; 44(12):1976-85. PubMed ID: 21098757
[TBL] [Abstract][Full Text] [Related]
9. New guideline for tramadol usage following adverse drug reactions reported to the Iranian Pharmacovigilance Center.
Gholami K; Shalviri G; Zarbakhsh A; Daryabari N; Yousefian S
Pharmacoepidemiol Drug Saf; 2007 Feb; 16(2):229-37. PubMed ID: 17063533
[TBL] [Abstract][Full Text] [Related]
10. Adverse drug reaction reporting by nurses: analysis of Italian pharmacovigilance database.
Conforti A; Opri S; D'Incau P; Sottosanti L; Moretti U; Ferrazin F; Leone R
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):597-602. PubMed ID: 22337264
[TBL] [Abstract][Full Text] [Related]
11. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
Olivier P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
[TBL] [Abstract][Full Text] [Related]
12. The EU-ADR Web Platform: delivering advanced pharmacovigilance tools.
Oliveira JL; Lopes P; Nunes T; Campos D; Boyer S; Ahlberg E; van Mulligen EM; Kors JA; Singh B; Furlong LI; Sanz F; Bauer-Mehren A; Carrascosa MC; Mestres J; Avillach P; Diallo G; Díaz Acedo C; van der Lei J
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):459-67. PubMed ID: 23208789
[TBL] [Abstract][Full Text] [Related]
13. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
14. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
15. Quality check of spontaneous adverse drug reaction reporting forms of different countries.
Bandekar MS; Anwikar SR; Kshirsagar NA
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1181-5. PubMed ID: 20845409
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of Kathmandu valley.
Jha N; Bajracharya O; Namgyal T
Kathmandu Univ Med J (KUMJ); 2007; 5(4):504-10. PubMed ID: 18604084
[TBL] [Abstract][Full Text] [Related]
17. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future.
Fabiano V; Mameli C; Zuccotti GV
Expert Opin Drug Saf; 2012 Jan; 11(1):95-105. PubMed ID: 21548838
[TBL] [Abstract][Full Text] [Related]
18. Pharmacovigilance systems and databases in Korea, Japan, and Taiwan.
Kimura T; Matsushita Y; Yang YH; Choi NK; Park BJ
Pharmacoepidemiol Drug Saf; 2011 Dec; 20(12):1237-45. PubMed ID: 21936017
[TBL] [Abstract][Full Text] [Related]
19. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system.
Chen CJ; Cheng CF; Lin HY; Hung SP; Chen WC; Lin MS
J Clin Pharm Ther; 2012 Dec; 37(6):647-51. PubMed ID: 22646235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
